{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"Ch14.18"},{"type":"Abbreviation","name":"MOAB Ch14.18"},{"type":"Synonym","name":"MOAB Ch14.18"},{"type":"Synonym","name":"monoclonal antibody Ch14.18"},{"type":"LexicalVariant","name":"Ch14.18 monoclonal antibody"},{"type":"INDCode","name":"4308"},{"type":"INDCode","name":"5748"},{"type":"NSCNumber","name":"623408"},{"type":"USBrandName","name":"Unituxin"},{"type":"ForeignBrandName","name":"Unituxin"},{"type":"ForeignBrandName","name":"Qarziba"},{"type":"CASRegistryName","name":"1363687-32-4"},{"type":"Synonym","name":"Ch 14.18UTC"},{"type":"Synonym","name":"dinutuximab beta"}],"definition":{"html":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","text":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/dinutuximab","text":"Dinutuximab"},"nciConceptId":"C1570","nciConceptName":"Dinutuximab","termId":42042,"name":"dinutuximab","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dinutuximab"}],"links":null}